A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Researchers discover that bone marrow cancer cells diversify drastically when exiting the bone marrow, which also affects the ...

Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer of the blood—also known as hematologic cancer. It affects cells called plasma cells, which are types of white ...

Although multiple myeloma currently remains an incurable disease, ongoing research and innovation offer hope for improving survival rates and quality of life. 1 We are getting closer to potential ...

Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated: ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population. The 66th ...

The mum went back to doctors, who found lesions on her skull and eye. They diagnosed her with multiple myeloma - an incurable blood cancer. According to the NHS, it claims the lives of 3,000 ...